R
Hi, I’m
Magdalena Schwarz
Health Economist
Wasserburg A. Inn,BY
Summary
Experienced health economist with proven expertise in market access and the strategic development of Data Generation Plans (DGPs) for vaccines across various life cycle stages. Successfully led cross-functional teams to implement DGPs, driving market access as well as medical evidence strategies and supporting global scientific objectives. Skilled in coordinating teams across Europe, Germany, and internationally to align with business and scientific goals.
Overview
10
years of professional experience
3
Languages
Work History
GlaxoSmithKline GmbH & Co. KG
ASSOCIATE DIRECTOR GLOBAL VALUE EVIDENCE AND OUTCOMES (VEO) CORE PORTFOLIO, PNEUMOCOCCAL VACCINES
03.2024 - 02.2025
Job overview
- Co-owned global Data Generation Plans (DGPs) for four multivalent pneumococcal vaccines (Phase I, II), supporting global scientific objectives, contributing to the development of vaccines with global market impact
- Led evidence gap analyses, ensuring alignment of DGPs with cross-functional teams, driving the strategic direction of vaccine development
- Managed internal governance submissions, securing resources and funding for DGP execution, enabling the timely and successful launch of vaccine candidates
- Identified and mitigated risks related to DGPs, ensuring alignment with global objectives and minimizing disruptions to project timelines
- Spearheaded the development of a dynamic transmission model (DTM) and cost-effectiveness analysis (CEA), influencing key decision-making processes at the global company level as well as delivering on data requirements from NITAGs in key markets such as Germany
- Contributed key inputs to the development of static cost-effectiveness models (CEM), delivering on NITAG's/HTA's data requirements (such as ACIP in U.S., JCVI/NICE in UK, HAS in France) to support decision making towards broad market access and reimbursement of future vaccines for patients
- Coordinated scientific engagement with external thought leaders, advancing the development of health economic modelling and non-interventional research for vaccine portfolios
- Co-authored a fast-track designation request to the U.S. FDA for a 24-valent pediatric pneumococcal vaccine, aimed at accelerating the regulatory approval process and paving the way for broader market access
GlaxoSmithKline GmbH & Co. KG
SENIOR MANAGER GLOBAL VEO EARLY DEVELOPMENT
08.2022 - 02.2024
Job overview
- Led the global strategic formulation and implementation of the Data Generation Plan (DGP) for a therapeutic HSV vaccine (Phase I/II), shaping the foundation for global market access and scientific development
- Proposed, set up, and delivered studies of the DGP, ensuring alignment with global objectives and optimizing the research process
- Led and supported external engagements, including patient roundtables, scientific advisory boards, consultations with global payer panels, HTAs, NITAGs and regulatory authorities, influencing market access strategies as well as clinical and non-interventional evidence plans and facilitating broad stakeholder alignment
- Initiated update to the early cost-effectiveness model (CEM) and pricing forecasts, contributing to informed pricing decisions and market positioning for the HSV vaccine
- Advised and led RWE/HEOR research, including retrospective analyses of claims data and health surveys, providing critical insights into disease burden and cost-of-illness across key markets (US, UK, Japan, Germany)
- Contributed to clinical trial designs, regulatory interactions, and RWE strategies, ensuring alignment with economic and humanistic endpoints, including leading a workstream to align patient-reported outcomes for Phase III trials
GlaxoSmithKline GmbH & Co. KG
MANAGER GERMAN MARKET ACCESS VACCINES
09.2019 - 07.2022
Job overview
- Secured funding and led the design and implementation of German Data Generation Plans (DGPs) for vaccines, with a main focus on RSV, Herpes Zoster, Neisseria, Pertussis, and Influenza, ensuring alignment with national market access needs
- Led or co-led local RWE/HEOR studies, including the German adaptation of the global meningococcal B DTM/CEA model, providing critical data to inform vaccine access and reimbursement strategies
- Co-led consultancies with external experts, including healthcare professionals and data scientists to inform RWE/HEOR studies such as prospective observational studies on RSV or claims database analysis for Pertussis, influencing national vaccination strategies and answering key questions from the medical scientific community
- Collaborated cross-functionally with local, European, and global teams to achieve consensus on German DGPs and developed communication strategies to disseminate study data to stakeholders
- Engaged with national authorities, including representatives from STIKO and RKI, to discuss DGPs and HEOR study outcomes, advocating for optimal market access and reimbursement
- Served as a subject matter expert in Market Access for vaccines, leading modelling studies, retrospective claims database analyses, and systematic literature reviews to shape vaccine market strategies
MASTER STUDENT WORKER GERMAN MARKET ACCESS
11.2018 - 08.2019
Job overview
- Master thesis titled "Seasonal and long-term incidence dynamics of invasive meningococcal disease (IMD) in Germany – a time series analysis" (programming conducted with R version 3.4.1)
- Supported the AMNOG dossier preparation according to 35a SGB V for a product in the indication Systemic Lupus Erythematosus
INTERN GERMAN MARKET ACCESS SPECIALTY AND VACCINES
09.2017 - 10.2018
Job overview
- Maintained the AMNOG process according to 35a SGB V (e.g., dossier submissions, advice consultations, written statements, oral hearings, price negotiations) for products targeting indications Asthma and HIV
- Supported conducting budget impact/cost-effectiveness analyses, coordinating internal workshops, health services research, and bibliographic and targeted literature searches in a national/international context
Institute for Medical Information Processing, Biometry and Epidemiology
STATISTICAL ANALYSIS TUTOR FOR SOFTWARE ‘STATISTICAL ANALYSIS SYSTEM (SAS)'
10.2016 - 05.2017
IQVIA (formerly IMS Health)
INTERN HEALTH ECONOMICS AND OUTCOMES RESEARCH
02.2015 - 08.2015
Job overview
- Supported preparations of AMNOG dossiers according to 35a SGB V
- Wrote a statistical analysis plan for a prospective observational study
Education
Ludwig Maximilian University of Munich
Master's Degree from Public Health
10.2016 - 2019.09
University Overview
GPA: 1.73
University of Applied Sciences of Rosenheim
Bachelor's Degree from Healthcare Management
10.2012 - 2016.10
University Overview
GPA: 1.6
Skills
Market Access
Software
SAS
Citavi
EndNote
Timeline
ASSOCIATE DIRECTOR GLOBAL VALUE EVIDENCE AND OUTCOMES (VEO) CORE PORTFOLIO, PNEUMOCOCCAL VACCINES
GlaxoSmithKline GmbH & Co. KG
03.2024 - 02.2025
SENIOR MANAGER GLOBAL VEO EARLY DEVELOPMENT
GlaxoSmithKline GmbH & Co. KG
08.2022 - 02.2024
MANAGER GERMAN MARKET ACCESS VACCINES
GlaxoSmithKline GmbH & Co. KG
09.2019 - 07.2022
MASTER STUDENT WORKER GERMAN MARKET ACCESS
11.2018 - 08.2019
INTERN GERMAN MARKET ACCESS SPECIALTY AND VACCINES
09.2017 - 10.2018
STATISTICAL ANALYSIS TUTOR FOR SOFTWARE ‘STATISTICAL ANALYSIS SYSTEM (SAS)'
Institute for Medical Information Processing, Biometry and Epidemiology
10.2016 - 05.2017
Ludwig Maximilian University of Munich
Master's Degree from Public Health
10.2016 - 2019.09
INTERN HEALTH ECONOMICS AND OUTCOMES RESEARCH
IQVIA (formerly IMS Health)
02.2015 - 08.2015
University of Applied Sciences of Rosenheim
Bachelor's Degree from Healthcare Management
10.2012 - 2016.10
Similar Profiles
Marcin SzulcMarcin Szulc
Sport data consultant at Sportdata GmbH & Co KGSport data consultant at Sportdata GmbH & Co KG
Laura FernandezLaura Fernandez
Management Assistant / Office Manager at Phoenix GmbH & Co. KGManagement Assistant / Office Manager at Phoenix GmbH & Co. KG
Marlous MaassMarlous Maass
Commercial Director at Trendwerkstudios GmbH & Co. KGCommercial Director at Trendwerkstudios GmbH & Co. KG